Archive for ‘Ventilator’

Facial Rejuvenation Market to Approach US$ 26,585.6 Mn by 2021

Facial Rejuvenation Market to Approach US$ 26,585.6 Mn by 2021

Skin-Treatment-5

 

The global facial rejuvenation market is expected to expand at a CAGR of 4.9% during the forecast period 2015-2021.

The market is segmented based on product type, end-user type, and region. On the basis of product type, the overall market has been segmented into topical products (sunscreens, moisturizers, keratolytic, retinoids, and hair removal creams), botulinum, dermal fillers, chemical peels, microabrasion equipment, and equipment-based treatments such as laser resurfacing and ultrasounds. On the basis of end-user, the market has been segmented into hospitals and dermatology clinics, which include private offices held by leading dermatologists. By product type, the botulinum products are expected to remain the largest segment, registering highest CAGR of 7% in terms of value, over the forecast period. The longer effectiveness of the treatment and easier availability is expected to contribute to its growing popularity. The botulinum product type segment is expected to reach a market value of US$ 9,796.9 Mn by the end of the forecast period. The product is also expected to emerge as the most preferred treatment type for both patients and physicians, globally, over the forecast period. The second most popular treatment choice is dermal fillers containing hyaluronic acid.

On the basis of the end user segment type, the market has been segmented into hospitals and dermatology clinics. Currently, clinics are more preferred to hospitals by patients globally.

On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia-Pacific, and the MEA.

Early onset of ageing and rising adoption of lesser painful minimally invasive or non-surgical rejuvenation procedures are major factors driving the growth of the global facial rejuvenation market currently. Other trends driving the market growth include easier access to treatments, rising affordability, increasing awareness about more innovative and less painful procedures, deeper penetration of beauty products in the local markets, and demand for quicker results and shorter treatment duration by patients. However, the market is expected to witness regulatory overhaul with an increase in procedure and product standardization during the forecast period (2015–2021).

The absence of standardized regulations is leading to an influx of many local players in both the developed and emerging regions. Furthermore, lack of documented and approved product efficacy is also hampering the growth of this market. Major players dominate the market in developed regions currently. Local players offer similar local products at 20% – 30% price discounts compared to that offered by renowned and established companies in North America and Europe. This leads to unhealthy competition and could also hamper patient safety.

This report assesses trends driving each market segment and offers analysis and insights about the potential of facial rejuvenation therapies in specific regions. North America is estimated to dominate the facial rejuvenation market with the maximum value share of the overall market by the end of 2015. By 2021, North America and Europe markets are expected to account for over three-fifth share of the global facial rejuvenation market revenue. In terms of value, North America is estimated to be the dominant market, registering a CAGR of 7.4% over the forecast period.

Request to view Table of Content @ http://www.persistencemarketresearch.com/market-research/facial-rejuvenation-market/toc

Some key companies covered in this report include Merz GmbH & Co. KGaA, LUMENIS, Revance Therapeutics, Inc., Biopolymer GmbH &Co KG, Speciality European Pharma, Mentor Worldwide LLC, Anika Therapeutics, Inc., Contura International A/S, Cynosure, Inc., Fibrocell, Inc., and Gal derma S/A. These companies are primarily focused on enhancing their product portfolio through research and development and on the introduction of innovative and cost-effective treatment procedures in order to gain higher market share and to strengthen their respective position in the global market.

To Purchase Single User License @ http://www.persistencemarketresearch.com/checkout/3639

The global facial rejuvenation market is segmented as follows:

By Product Type

  • Topical Rejuvenation Products
    • Keratolytics
    • Moisturizers
    • Retinoids
    • Sunscreens
    • Hair Removals
  • Botulinum Products
  • Dermal Fillers
    • Absorbable Dermal Fillers
    • Non Absorbable Dermal Fillers
  • Chemical Peels
  • Micro Abrasion Equipment
  • Equipment
    • Laser Based Equipment
    • Ultrasound Based Equipment

By End Use

  • Hospitals
  • Dermatology Clinics

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States

USA – Canada Toll Free: +1 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Full story

HeartWare Ventricular Assist System Receives FDA Approval as Bridge to Heart Transplantation

HeartWare Ventricular Assist System Receives FDA Approval as Bridge to Heart Transplantation

HeartWare Ventricular Assist System Receives FDA Approval as Bridge to Heart Transplantation

The Sydney Morning Herald is reporting that a local company HeartWare Ltd., is developing “the smallest of the third generation left ventricular assist devices (LVAD) available in the market, and being the smallest is very big news.” The newspaper also reports that the firm has implanted its HVAD, a left ventricular assist device, into a 48 year old Austrian patient with heart failure.

Here is how the company describes its technology:

HeartWare’s technology is based on the use of a wide bladed impeller designed to achieve optimum performance and haemocompatibility, size minimisation, long term reliability and overall system efficiencies.

The impeller is the only moving part in the HeartWare device. The impeller is held in place by a proprietary hybrid magnetic and hydrodynamic bearing system. The wide blades of the impeller contain large motor magnets, so the same space is used for pump and motor elements, achieving design efficiencies. The rare earth magnets in the impeller do not require electricity in order to induce their magnetic effect, thereby minimising the need for wires and connections, further simplifying the design and improving reliability. The result is a compact, energy efficient device, wearless, reliable and shock resistant, and designed to provide full cardiac output with optimal haemocompatibility.

341424 Medical Heart Pumps from HeartWare: HVAD, MVAD and PedVAD

Important additional features of the technology include two motor stators providing redundancy, a proprietary integrated inflow cannula enabling pericardial implantation, and electrical leads based on pacemaker technology.

Even though it is not clear to us how the device is attached to the heart or aorta (or else), here is some information about the HVAD:

With a volume of only 45cc, the HVAD is the smallest full output long term circulatory assist device under development. HeartWare believes the HVAD to be the only device of its type that can be implanted in the space directly surrounding the heart, rather than in the abdomen. This leads to significant potential advantages, particularly in terms of the ease of surgical implantation and consequent patient benefits.

We also understand that the company is trying to bring to the market another miniaturised ventricular assist device (named MVAD) and a pedi version, the PedVAD, for infants with heart failure.

HeartWare Receives FDA Approval for HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart Failure

- First full-support, miniaturized ventricular assist device approved in U.S. designed to be placed in the pericardial space -

- HeartWare Management to Host Investor Conference Call Today at 3:00 pm ET -

FRAMINGHAM, Mass. and SYDNEY, Nov. 20, 2012 /PRNewswire/ — HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare® Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.

(Photo: http://photos.prnewswire.com/prnh/20121120/LA17073)

The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HVAD pump, with sintered inflow cannula, weighs approximately 5 ounces and displaces a volume of approximately 50 milliliters. The HeartWare System is intended for use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure.

The HeartWare System is currently the leading ventricular assist device implanted in patients outside of the United States, having received CE Marking in the European Union in 2009, and Australian Therapeutic Goods Administration (TGA) approval in 2011. Today, more than 2,500 advanced heart failure patients globally have received the HVAD® pump.

“FDA approval marks the culmination of an extensive clinical effort and represents an exciting advance in the treatment of late-stage heart failure patients,” said Doug Godshall, President and Chief Executive Officer of HeartWare. “We wish to extend our most sincere thanks to the patients, and to their families, for participating in the study of this innovative device, and we also are grateful to each of the nurses, coordinators, surgeons and cardiologists who provided care to those patients.”

Achieving long-standing goals

“I’ve had the opportunity to work on the HVAD® project since its conception over a decade ago. The goal was to develop a miniaturized device with an integrated inflow cannula that could be placed within the pericardial sac, avoiding the necessity of creating a pump pocket with its attendant infection risks, as well as simplifying the surgical insertion,” stated O.H. “Bud” Frazier, MD; Chief, Center for Cardiac Support; Director, Cardiovascular Surgery Research; and Co-Director, Cullen Cardiovascular Research Laboratories, at Texas Heart Institute and a global pioneer in mechanical circulatory support. “A second goal was elimination of mechanical bearings to suspend the impeller, designed to enhance durability and blood handling characteristics. Those of us who treat these challenging end-stage heart failure patients are fortunate to have this pericardial, wearless system available for our patients.”

Commencing Commercialization

“Our team is positioned to commence the commercial rollout of the HeartWare System immediately, first facilitating broad use by the 50 U.S. hospitals that participated in our clinical studies, and then with training and expansion to additional U.S. hospitals,” added Mr. Godshall. “As always, HeartWare remains committed to enhancing outcomes for patients with end-stage heart failure and we will continue working to improve the overall clinical experience with the HVAD.”

HeartWare’s pre-market approval (PMA) submission included data from the Company’s pivotal ADVANCE clinical trial, an FDA approved Investigational Device Exemption (IDE) study designed to evaluate the HeartWare System as a bridge to heart transplantation for patients with end-stage heart failure. Under ADVANCE, 140 patients at 30 hospitals in the U.S. received the HeartWare investigational device between August 2008 and February 2010. The ADVANCE study achieved a 94% survival at 6 months and successfully met its primary endpoint of establishing non-inferiority between the investigational device and comparator arm of the study, which was derived from contemporaneous patients from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) [p

To help assure the continued safety and effectiveness of an approved device, FDA requires a post-approval study (PAS) as a condition of approval under 21 CFR 814.82(a)(2) to assess device performance in a real-world setting. HeartWare’s PAS is a registry consisting of 600 patients who receive an HVAD and an additional 600 control patients derived from a contemporaneous group of continuous flow, intra-corporeal LVAD patients entered into the INTERMACS database. The data for both arms of the study will be entered into the INTERMACS registry by the implanting centers. Other post approval commitments include the transfer of patients from the ADVANCE IDE study into a post approval database as well as an obligation to continue training sites in accordance with an approved training program.

In other clinical development for the HeartWare Ventricular Assist System, HeartWare has completed enrollment of a 450-patient destination therapy study at 50 U.S. sites. The final patients were implanted in May 2012, with a two-year, primary endpoint follow-up period. HeartWare has requested a Continued Access Protocol allocation for destination therapy from the FDA.

Conference Call

HeartWare will host a conference call today at 3:00 p.m. U.S. Eastern Time to discuss approval of the HeartWare® Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure. The call may be accessed by dialing 1-855-235-2089 five minutes prior to the scheduled start time and referencing “HeartWare.” For callers outside the U.S., please dial +1-778-327-3988.

A live webcast of the call will also be available at the Company’s website (www.heartware.com) by selecting “HeartWare FDA Approval Conference Call” under the section titled “Corporate Presentations” on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, and has received CE Marking in the European Union and has been used to treat patients in 27 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company’s website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE®, HVAD®, MVAD® and HeartWare logos are registered trademarks of HeartWare, Inc.

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the progress of clinical trials and post-approval studies, regulatory approvals, research and development activities and commercialization strategies. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission. We may update our risk factors from time to time in Part II, Item 1A “Risk Factors” in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

Overview

HeartWare is developing a family of Left Ventricular Assist Devices (“LVADs”) for the treatment of advanced heart failure. Through a cadence of progressively smaller devices, implanted with progressively less invasive surgery, HeartWare expects to treat an increasing proportion of heart failure patients and to access patients at an earlier stage of their disease progression. HeartWare’s lead product, the HeartWare® Ventricular Assist System, has been approved for sale in the European Union and is currently the subject of a clinical trial in the United States.

An LVAD is a surgically implanted mechanical pump designed to supplement the reduced blood pumping capability of a patient’s failing heart. LVADs have been in clinical use for more than twenty years, predominantly as a means of supporting, or “bridging”, a patient until a donor heart becomes available. Historically, the technical limitations of these devices have restricted their use to this relatively small “Bridge to Transplant” patient population and have limited their acceptance as a potential long-term alternative to transplantation. This has been changing as device technology has improved, and LVADS are potentially becoming a long-term support option for patients.

Key features of HeartWare’s technology platform include:

“Wearless” Suspension Mechanism

At the core of the HeartWare platform is the proprietary use of a “hybrid” system for suspending the impeller (or rotor), the only moving part within the pump. The impeller is suspended using a combination of passive magnets and hydrodynamic thrust bearings. The hydrodynamic thrust bearings work by establishing a “cushion” of blood between the impeller and the pump housing. Once power is applied to the device and the impeller begins to rotate, there are no points of mechanical contact within the pump, effectively ensuring a “wearless” system.

The elimination of mechanical bearings is expected to lead to longer term device reliability and to reduced risk of physical damage to blood cells as they pass through the pump.

Miniaturization

The hybrid suspension system also allows HeartWare to significantly downsize its pump technology. The HeartWare Ventricular Assist System features a miniaturized centrifugal pump, the HVAD® pump, which is small enough to be implanted above the diaphragm. Reduced procedural invasiveness is expected to lead to more rapid post-operative recovery and improved patient outcomes. Beyond the HVAD pump, HeartWare is developing a family of further miniaturized pumps that may be implanted using less invasive surgical techniques.

Optimal Blood Flow Paths

A key clinical requirement of LVAD technology is minimal damage to the blood, either in the form of thrombus (blood clotting) or hemolysis (rupturing of blood cell membranes).

The HVAD pump employs a proprietary “wide bladed” impeller, designed to provide optimal blood flow paths through the system. The HVAD pump also incorporates an integrated inflow cannula, ensuring proximity between the heart and the pump itself. This proximity is expected to eliminate potential points of blood turbulence or stasis through the system.

HeartWare, an Australian and Framingham, Massachusetts developer of ventricular assist devices, has received FDA approval for its HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure. Key features of the device are its small size and lack of mechanical bearings.

HeartWare Ventricular Assist System side HeartWare Ventricular Assist System Receives FDA Approval as Bridge to Heart Transplantation (VIDEO)

The pump is small enough to be implanted in the pericardial space, directly adjacent to the heart, avoiding the necessity of creating a pump pocket with its attendant infection risks, as well as simplifying the surgical insertion. The single moving part of the pump, the impeller, is suspended within the pump housing through a combination of passive magnets and hydrodynamic thrust bearings, eliminating wear while spinning at rates between 2,400 and 3,200 revolutions per minute.

From HeartWare:

The HeartWare Ventricular Assist System features the HVAD pump, a small full-support circulatory assist device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HVAD pump, with sintered inflow cannula, weighs approximately 5 ounces and displaces a volume of approximately 50 milliliters. The HeartWare System is intended for use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure.

The HeartWare System is currently the leading ventricular assist device implanted in patients outside of the United States, having received CE Marking in the European Union in 2009, and Australian Therapeutic Goods Administration (TGA) approval in 2011. Today, more than 2,500 advanced heart failure patients globally have received the HVAD pump.

FDA approval follows on positive results of the ADVANCE trial, which showed non-inferiority compared to other ventricular assist devices in end-stage heart failure patients. Additionally, in efforts to broaden the clinical indications, HeartWare has completed enrollment of a destination therapy study last May, but results will only be available when the two-year primary endpoint follow-up period has been reached. Commercial roll-out of the HeartWare System will start with the 50 U.S. hospitals that participated in HeartWare’s clinical studies, after which additional hospitals will follow.

http://www.youtube.com/watch?v=v8aIeoHXTMw&feature=player_embedded

Source : http://ir.heartware.com/phoenix.zhtml?c=187755&p=irol-newsArticle&ID=1760867

Full story

Researchers develop bioactive coating that actively suppresses brain’s immune response

Researchers develop bioactive coating that actively suppresses brain’s immune response

Brain-computer interfaces are at the cutting edge for treatment of neurological and psychological disorder, including Parkinson’s, epilepsy, and depression. Among the most promising advance is deep brain stimulation (DBS) – a method in which a silicon chip implanted under the skin ejects high frequency currents that are transferred to the brain through implanted electrodes that transmit and receive the signals. These technologies require a seamless interaction between the brain and the hardware.

But there’s a catch. Identified as foreign bodies by the immune system, the brain attacks the electrodes and forms a barrier to the brain tissue, making it impossible for the electrodes to communicate with brain activity. So while the initial implantation can diminish symptoms, after a few short years or even months, the efficacy of this therapy begins to wane.

Now Aryeh Taub of Tel Aviv University’s School of Psychological Sciences, along with Prof. Matti Mintz, Roni Hogri and Ari Magal of TAU’s School of Psychological Sciences and Prof. Yosi Shacham-Diamand of TAU’s School of Electrical Engineering, has developed a bioactive coating which not only “camouflages” the electrodes in the brain tissue, but actively suppresses the brain’s immune response. By using a protein called an “interleukin (IL)-1 receptor antagonist” to coat the electrodes, the multi-disciplinary team of researchers has found a potential resolution to turn a method for short-term relief into a long-term solution. This development was reported in the Journal of Biomedical Materials Research.

Limiting the immune response

To overcome the creation of the barrier between the tissue and the electrode, the researchers sought to develop a method for placing the electrode in the brain tissue while hiding the electrode from the brain’s immune defenses. Previous research groups have coated the electrodes with various proteins, says Taub, but the TAU team decided to take a different approach by using a protein that is active within the brain itself, thereby suppressing the immune reaction against the electrodes.

In the brain, the IL-1 receptor antagonist is crucial for maintaining physical stability by localizing brain damage, Taub explains. For example, if a person is hit on the head, this protein works to create scarring in specific areas instead of allowing global brain scarring. In other words, it stops the immune system from overreacting. The team’s coating, the first to be developed from this particular protein, not only integrates the electrodes into the brain tissue, but allows them to contribute to normal brain functioning.

In pre-clinical studies with animal models, the researchers found that their coated electrodes perform better than both non-coated and “na-ve protein”-coated electrodes that had previously been examined. Measuring the number of damaged cells at the site of implantation, researchers found no apparent difference between the site of electrode implantation and healthy brain tissue elsewhere, Taub says. In addition, evidence suggests that the coated electrodes will be able to function for long periods of time, providing a more stable and long-term treatment option.

Restoring brain function

Approximately 30,000 people worldwide are currently using deep brain stimulation (DBS) to treat neurological or psychological conditions. And DBS is only the beginning. Taub believes that, in the future, an interface with the ability to restore behavioral or motor function lost due to tissue damage is achievable – especially with the help of their new electrode coating.

“We duplicate the function of brain tissue onto a silicon chip and transfer it back to the brain,” Taub says, explaining that the electrodes will pick up brain waves and transfer these directly to the chip. “The chip then does the computation that would have been done in the damaged tissue, and feeds the information back into the brain – prompting functions that would have otherwise gotten lost.”

Source : http://www.news-medical.net/news/20120801/

www.Researchers-develop-bioactive-coating-that-actively-suppresses-brains-immune-response.aspx?page=1

Full story

Ventilator : AV-2000B2

Ventilator : AV-2000B2

Ventilator  AV-2000B2
■ Display
8.4 high-definition TFT color LCD Display
■ ventilation
Intermittent positive pressure ventilation IPPV
Synchronized intermittent positive pressure ventilation SIPPV
Synchronized intermittent mandatory ventilation SIMV
PEEP PEEP
Artificial MANU
Sigh SIGH
■ ventilation parameters
Tidal volume 0 ~ 1500ml
Frequency of 4 to 60 beats / min
Respiratory than 2:1 to 1:8
- Trigger sensitivity -0.1 ~ 1.0KPa
PEEP 0 ~ 1.0KPa
1 ~ 6Kpa pressure control
Sigh 1.5 inspiratory time
Inspiratory Ping-0 ~ 50% inspiratory time
■ ventilation monitoring
Tidal volume, ventilation, IPPV frequency of respiratory ratio, peak airway pressure, the pressure – time waveform,
Velocity – time waveform, the respiratory rate, positive end-expiratory pressure, suction trigger pressure, suction Ping Desk,
Average pressure, oxygen concentration
■ monitoring oxygen concentration of 15% to 100%
■ Security Alarm System
Alarm capped oxygen concentration range of 50% to 100%
Set minimum of 15% ~ 50%
Alarm airway pressure cap of 1 ~ 6 KPa
Set minimum of 0.4 ~ 2KPa
Alarm minute ventilation cap of 3.0 to 30 L / min
Set minimum of 1 ~ 10L/min
Suffocation alarm no tidal volume of 15 s, sound, light alarm
Power alarm
■ Power AC 220V ± 10% 50Hz ± 1Hz
UPS power supply, battery (optional)

Ventilator ■ Display     8.4 high-definition TFT color LCD Display ■ ventilation     Intermittent positive pressure ventilation IPPV     Synchronized intermittent positive pressure ventilation SIPPV     Synchronized intermittent mandatory ventilation SIMV     PEEP PEEP     Artificial MANU     Sigh SIGH ■ ventilation parameters     Tidal volume 0 ~ 1500ml     Frequency of 4 to 60 beats / min     Respiratory than 2:1 to 1:8     – Trigger sensitivity -0.1 ~ 1.0KPa     PEEP 0 ~ 1.0KPa     1 ~ 6Kpa pressure control     Sigh 1.5 inspiratory time     Inspiratory Ping-0 ~ 50% inspiratory time ■ ventilation monitoring     Tidal volume, ventilation, IPPV frequency of respiratory ratio, peak airway pressure, the pressure – time waveform,     Velocity – time waveform, the respiratory rate, positive end-expiratory pressure, suction trigger pressure, suction Ping Desk,     Average pressure, oxygen concentration ■ monitoring oxygen concentration of 15% to 100% ■ Security Alarm System     Alarm capped oxygen concentration range of 50% to 100%                      Set minimum of 15% ~ 50%     Alarm airway pressure cap of 1 ~ 6 KPa                      Set minimum of 0.4 ~ 2KPa     Alarm minute ventilation cap of 3.0 to 30 L / min                      Set minimum of 1 ~ 10L/min     Suffocation alarm no tidal volume of 15 s, sound, light alarm     Power alarm ■ Power AC 220V ± 10% 50Hz ± 1Hz                UPS power supply, battery (optional)

Full story

AV-2000B1 Ventilator

AV-2000B1 Ventilator

AV-2000B1
The AV-2000B1 multi-purpose life-support machines are suitable for the children, the adults, widely used in the
hospital wards, ICU, A & E.
Main technical parameters
Main technical parameters
Ventilator
■Display mode 5.7-inch 8.4-inch high clear display
■Ventilation mode
IPPV(intermittent positive pressure ventilation)
SIPPV(synchronized intermittent positive pressure ventilation) SIMV(synchronized intermittent mandatory ventilation)
PEEP(expiration end positive pressure)
MANUAL(manual work)
SIGH
■Ventilation parameters
Tidal volume   50~1500ml
Frequency   4~60/min
Inspiratory time/expiratory time ratio   2:1~1:8
Trigger sensitivity   -0.1~-1.0KPa
PEEP   0~1.0KPa
Pressure control   1~6KPa
Sigh    1.5 inspiratory times
■Ventilation monitoring
Tidal volume、Ventilation capacity、IPPV frequency、Breathing frequency、Inspiratory ime/expiratory time ratio、Peak &#118alue of airway pressure、Pressure-time wave、Flow rate-time wave、Breathing frequency、End-expiratory positive pressure、 Inspiratory trigger pressure、 (Inspiratory trigger
pressure、Inspiratory pause)
■(Oxygen concentration monitor 21%~100% )
■Safety alarm systems
(Oxygen concentration alarm ) Upper limit setting range 50%~1                          Low limit setting range 15%~50%
Airway pressure alarm                                               Upper limit setting range 1.5~6.0KPa
Low limit setting range 0.2~3.0KPa
Minute volume alarm Upper limit setting range 2.0~30L/min
Low limit setting range 1~12L/min
Asphyxia alarm     The machine will give sound and light alarm if there is no
tidal volume more than 15s
Power failure alarm
■Power supply   AC 220V±10%   50Hz±1Hz
UPS、 Battery (choose and match)
Attention: In the above parenthesis the content is 8.4 inch colored tablet life-support machine’s parameter

AV-2000B1  The AV-2000B1 multi-purpose life-support machines are suitable for the children, the adults, widely used in the  hospital wards, ICU, A & E.   Main technical parameters   Main technical parameters   Ventilator   ■Display mode 5.7-inch 8.4-inch high clear display   ■Ventilation mode   IPPV(intermittent positive pressure ventilation)   SIPPV(synchronized intermittent positive pressure ventilation) SIMV(synchronized intermittent mandatory ventilation)  PEEP(expiration end positive pressure)   MANUAL(manual work)   SIGH   ■Ventilation parameters   Tidal volume   50~1500ml   Frequency   4~60/min   Inspiratory time/expiratory time ratio   2:1~1:8   Trigger sensitivity   -0.1~-1.0KPa   PEEP   0~1.0KPa   Pressure control   1~6KPa   Sigh    1.5 inspiratory times   ■Ventilation monitoring   Tidal volume、Ventilation capacity、IPPV frequency、Breathing frequency、Inspiratory ime/expiratory time ratio、Peak &#118alue of airway pressure、Pressure-time wave、Flow rate-time wave、Breathing frequency、End-expiratory positive pressure、 Inspiratory trigger pressure、 (Inspiratory trigger pressure、Inspiratory pause)   ■(Oxygen concentration monitor 21%~100% )   ■Safety alarm systems   (Oxygen concentration alarm ) Upper limit setting range 50%~1                          Low limit setting range 15%~50%   Airway pressure alarm                                               Upper limit setting range 1.5~6.0KPa   Low limit setting range 0.2~3.0KPa   Minute volume alarm Upper limit setting range 2.0~30L/min   Low limit setting range 1~12L/min   Asphyxia alarm     The machine will give sound and light alarm if there is no tidal volume more than 15s   Power failure alarm   ■Power supply   AC 220V±10%   50Hz±1Hz   UPS、 Battery (choose and match)   Attention: In the above parenthesis the content is 8.4 inch colored tablet life-support machine’s parameter

Full story

AV-2000B portable ventilator

AV-2000B portable ventilator

AV-2000B portable ventilator

■ Display 5.7 high-definition LCD Display ■ ventilation Intermittent positive pressure ventilation IPPV Synchronized intermittent positive pressure ventilation SIPPV Synchronized intermittent mandatory ventilation SIMV PEEP PEEP Manual ventilation MANU Sigh SIGH ■ ventilation parameters Tidal volume of 50 ~ 1500ml Frequency of 4 to 60 beats / min Respiratory than 2:1 to 1:8 – Trigger sensitivity -0.2 ~ 1.0KPa PEEP 0 ~ 1.0KPa 1 ~ 6KPa pressure control Sigh 1.5 inspiratory time ■ ventilation monitoring Tidal volume, ventilation, IPPV frequency of respiratory ratio, peak airway pressure, the pressure – time waveform, Velocity – time waveform, the respiratory rate, positive end-expiratory pressure, suction pressure trigger ■ Security Alarm System Alarm airway pressure cap of 1 ~ 6 KPa Set minimum of 0.4 ~ 2KPa Alarm minute ventilation cap of 3.0 to 30 L / min Set minimum of 1 ~ 10L/min Suffocation alarm no tidal volume of 15 s, sound, light alarm Power alarm ■ Power AC 220V ± 10% 50Hz ± 1Hz UPS power supply, battery (optional)

http://www.highsunmedical.com/Ventilator%20AV-2000B.htm

Full story

AV-2000B3 Ventilator

AV-2000B3 Ventilator

AV-2000B3


The AV-2000B3 Ventilator is a model of multi-purpose life-support machine. This machine uses the air operated electric control, the microcomputer technology. Selects imports the primary device to guarantee the equipment movement stably reliable. Colored (TFT) the screen demonstrates each kind of examination and the establishment parameter, which is a section of ideal breath treatment plant. It is suitable in all levels of hospitals inside and outside, woman, son, first aid, ICU and so on for the administrative offices equipments Main technical parameters

■Display mode 10.4-inch high clear color display

■Ventilation mode IPPV(intermittent positive pressure ventilation) SIPPV(synchronized intermittent positive pressure ventilation) IMV(intermittent mandatory ventilation) SIMV(synchronized intermittent mandatory ventilation) PCV(pressure control ventilation) PEEP/CPAP(Expiration end positive pressure/continuous positive airway pressure) SIGH

■Ventilation parameters Tidal volume 50~1500ml Frequency 4~80/min Inspiratory time/expiratory time ratio 4:1~1:4 SIMV Frequency 1~8/min Trigger sensitivity -0.1~-1.0KPa PEEP 0.1~1.0KPa Pressure control 1~6KPa Inspiratory pause 10~50% inspiratory time Sigh control breathing in a deep breath every 10~120 times/min. Inspiratory time is 1.5 times to the settings.

■Ventilation monitoring Tidal volume、Ventilation capacity、IPPV frequency、Breathing frequency、Inspiratory ime/expiratory time ratio、Peak &#118alue of airway pressure、Pressure-time wave、Flow rate-time wave、Breathing frequency、End-expiratory positive pressure、 Inspiratory trigger pressure(Inspiratory trigger pressure、Inspiratory pause)

■(Oxygen concentration monitor 21%~100% )

■Safety alarm systems Airway pressure alarm Upper limit setting range 0~6.0KPa Low limit setting range 0~5.0KPa Tidal volume Upper limit setting range 0~2000ml Low limit setting range 0~1800ml Oxygen concentration alarm Upper limit setting range 21%~100% Low limit setting range 0%~80% Asphyxia alarm The machine will give sound and light alarm if there is no tidal volume in15s Power failure alarm ■Power AC 220V±10% 50Hz±1Hz UPS、 Battery (choose and match)

http://www.highsunmedical.com/Ventilator%20AV-2000B3.htm

Related Posts Plugin for WordPress, Blogger...

Full story

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes